Cees J. van Groeningen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cees J. van Groeningen has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- H. M. Pinedo
VU Univ Medcl Ctr, Amsterdam, The Netherlands; Janssen-Cilag, Tilburg, The Netherlands; Johnson & Johnson PRD, Beerse, Belgium
18 shared publications - Godefridus J. Peters
Department of Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
6 shared publications J B Vermorken
4 shared publications- Giuseppe Giaccone
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
3 shared publications H E Gall
3 shared publicationsA Leyva
2 shared publications
Latest Publications
- 30 September 2009
- Published by Elsevier in European Journal of Cancer
- Vol. 45 (14) , 2519-2527
A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion
- 30 September 2009
- Published by Elsevier in European Journal of Cancer
- Vol. 45 (14) , 2519-2527
A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion
- 1 January 2006
- Published by Taylor & Francis in Cancer Investigation
- Vol. 24 (6) , 562-566
Iron Absorption During Epoetin Alfa Therapy for Chemotherapy-Associated Anaemia
Absorption of a physiological dose of ferrous iron was studied in 18 patients with solid malignancy receiving epoetin therapy for mild chemotherapy-associated anemia. The historical control group consisted of 25 iron replete volunteers (iron absorption 20 ± 11% in males and 26 ± 13% in females) and 21 patients with uncomplicated iron deficiency (iron absorption 71 ± 19%). Iron absorption was increased in the majority of the cancer patients (iron absorption 59 ± 35%). There were no significant differences in iron absorption between cancer patients who were iron replete or iron deficient according to current clinical practice guidelines (iron deficiency: transferrin saturation < 20% and/or serum ferritin < 100 ng/mL). Red cell iron incorporation was not disturbed in the majority (89%) of patients.
- 1 January 2006
- Published by Taylor & Francis in Cancer Investigation
- Vol. 24 (6) , 562-566
Iron Absorption During Epoetin Alfa Therapy for Chemotherapy-Associated Anaemia
Absorption of a physiological dose of ferrous iron was studied in 18 patients with solid malignancy receiving epoetin therapy for mild chemotherapy-associated anemia. The historical control group consisted of 25 iron replete volunteers (iron absorption 20 ± 11% in males and 26 ± 13% in females) and 21 patients with uncomplicated iron deficiency (iron absorption 71 ± 19%). Iron absorption was increased in the majority of the cancer patients (iron absorption 59 ± 35%). There were no significant differences in iron absorption between cancer patients who were iron replete or iron deficient according to current clinical practice guidelines (iron deficiency: transferrin saturation < 20% and/or serum ferritin < 100 ng/mL). Red cell iron incorporation was not disturbed in the majority (89%) of patients.
- 5 May 2001
- Vol. 145 (18) , 878-81
[Decline in the need for blood transfusions in cancer patients due to the use of epoietin alfa during cisplatin based chemotherapy].
To compare the need for blood transfusions between two groups of patients treated with cisplatin-containing chemotherapy. One of these groups received epoetin alpha therapy. Prospective with an historical control group. From April 1998 to December 1999, 44 patients who were being treated with cisplatin and gemcitabine were also administered epoetin alpha (10,000 U subcutaneously, thrice weekly) from the onset of anaemia. The need for red blood cell transfusions in this group was compared to a historical control group of 46 patients treated with the same combination chemotherapy regimen from November 1995 to July 1997. In the historical control group, each patient received an average of 1.6 red blood cell transfusions as compared to 0.7 in the epoetin alpha group (a 58% reduction). The average number of units of red blood cells transfused per patient was 3.6 for the control group and 1.8 for the epoetin alpha group (a 50% reduction). In the epoetin alpha group, none of the patients received more than 2 transfusions whereas in the control group, 10 patients (22%) received 3 or more transfusions. In two patients, epoetin therapy had to be stopped due to the occurrence of hypertension. Epoetin alpha reduced the need for red blood cell transfusions during cisplatin-containing chemotherapy. Its toxic effect was minimal.
- 5 May 2001
- Vol. 145 (18) , 878-81
[Decline in the need for blood transfusions in cancer patients due to the use of epoietin alfa during cisplatin based chemotherapy].
To compare the need for blood transfusions between two groups of patients treated with cisplatin-containing chemotherapy. One of these groups received epoetin alpha therapy. Prospective with an historical control group. From April 1998 to December 1999, 44 patients who were being treated with cisplatin and gemcitabine were also administered epoetin alpha (10,000 U subcutaneously, thrice weekly) from the onset of anaemia. The need for red blood cell transfusions in this group was compared to a historical control group of 46 patients treated with the same combination chemotherapy regimen from November 1995 to July 1997. In the historical control group, each patient received an average of 1.6 red blood cell transfusions as compared to 0.7 in the epoetin alpha group (a 58% reduction). The average number of units of red blood cells transfused per patient was 3.6 for the control group and 1.8 for the epoetin alpha group (a 50% reduction). In the epoetin alpha group, none of the patients received more than 2 transfusions whereas in the control group, 10 patients (22%) received 3 or more transfusions. In two patients, epoetin therapy had to be stopped due to the occurrence of hypertension. Epoetin alpha reduced the need for red blood cell transfusions during cisplatin-containing chemotherapy. Its toxic effect was minimal.
- 14 July 2000
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (14) , 2772-2779
Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid Tumors
PURPOSE: To investigate the side effects, determine the maximum-tolerated dose (MTD), and study the pharmacokinetics of S-1, an oral fluoropyrimidine-based antineoplastic agent consisting of the fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate. PATIENTS AND METHODS: Patients with advanced solid tumors received S-1 bid for 28 days, followed by 1 week of rest. 5-FU pharmacokinetics were investigated after a single initial dose of S-1 during the first 24 hours and weekly thereafter. RESULTS: Twenty-eight patients received S-1 at the four consecutive dose levels of 25, 45, 35, and 40 mg/m2. The MTD was initially found at 45 mg/m2, with diarrhea as the dose-limiting toxicity (DLT). Diarrhea was also the DLT at the dose of 40 mg/m2, which was the MTD for patients exposed to extensive prior chemotherapy. Other toxicities were generally mild. Two patients had a reduction of more than 50% in tumor dimension. Plasma pharmacokinetics of 5-FU were linear; at the highest S-1 dose level, 5-FU plasma peak concentrations reached 1 to 2 μmol/L, and the half-life of 5-FU was 3 to 4 hours. A statistically significant relationship was observed between the severity of diarrhea and pharmacokinetic parameters of 5-FU. CONCLUSION: The recommended dose of S-1 in chemotherapy-naive or minimally chemotherapy-exposed patients is 40 mg/m2 bid on 28 consecutive days, every 5 weeks. In heavily pretreated patients, the recommended dose is 35 mg/m2 bid. Phase II trials are warranted in tumors known to be responsive to 5-FU treatment.
- 14 July 2000
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (14) , 2772-2779
Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid Tumors
PURPOSE: To investigate the side effects, determine the maximum-tolerated dose (MTD), and study the pharmacokinetics of S-1, an oral fluoropyrimidine-based antineoplastic agent consisting of the fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate. PATIENTS AND METHODS: Patients with advanced solid tumors received S-1 bid for 28 days, followed by 1 week of rest. 5-FU pharmacokinetics were investigated after a single initial dose of S-1 during the first 24 hours and weekly thereafter. RESULTS: Twenty-eight patients received S-1 at the four consecutive dose levels of 25, 45, 35, and 40 mg/m2. The MTD was initially found at 45 mg/m2, with diarrhea as the dose-limiting toxicity (DLT). Diarrhea was also the DLT at the dose of 40 mg/m2, which was the MTD for patients exposed to extensive prior chemotherapy. Other toxicities were generally mild. Two patients had a reduction of more than 50% in tumor dimension. Plasma pharmacokinetics of 5-FU were linear; at the highest S-1 dose level, 5-FU plasma peak concentrations reached 1 to 2 μmol/L, and the half-life of 5-FU was 3 to 4 hours. A statistically significant relationship was observed between the severity of diarrhea and pharmacokinetic parameters of 5-FU. CONCLUSION: The recommended dose of S-1 in chemotherapy-naive or minimally chemotherapy-exposed patients is 40 mg/m2 bid on 28 consecutive days, every 5 weeks. In heavily pretreated patients, the recommended dose is 35 mg/m2 bid. Phase II trials are warranted in tumors known to be responsive to 5-FU treatment.
- 1 April 2000
- Vol. 6 (4) , 1342-6
Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines.
Metabolic conversion of CPT-11 is a major route of elimination of this new topoisomerase 1 inhibitor. Presently, recommendations for dose adjustments of CPT-11 in patients with liver dysfunction are lacking. We describe the case of a patient with metastatic colon cancer with liver dysfunction treated with CPT-11 at two different dose levels (100 mg/m2 and 30 mg/m2, single dose, administered as a 90-min i.v. infusion). The lactones and carboxylates of CPT-11 and SN-38 were determined by high-performance liquid chromatography. SN-38 glucuronide was determined after deglucuronidation. The procedures allowed intrapatient comparison of pharmacokinetics and metabolism of the drug. Severe side effects were encountered, which could be explained by the reduced clearance of CPT-11 and its metabolites. These included neutropenic fever with culture-proven septicemia, thrombocytopenia, somnolence, diarrhea, and signs and symptoms of transient hepatic failure. Our findings offer important data for the further development of guidelines for dose reduction of CPT-11 in patients with liver dysfunction.
- 1 April 2000
- Vol. 6 (4) , 1342-6
Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines.
Metabolic conversion of CPT-11 is a major route of elimination of this new topoisomerase 1 inhibitor. Presently, recommendations for dose adjustments of CPT-11 in patients with liver dysfunction are lacking. We describe the case of a patient with metastatic colon cancer with liver dysfunction treated with CPT-11 at two different dose levels (100 mg/m2 and 30 mg/m2, single dose, administered as a 90-min i.v. infusion). The lactones and carboxylates of CPT-11 and SN-38 were determined by high-performance liquid chromatography. SN-38 glucuronide was determined after deglucuronidation. The procedures allowed intrapatient comparison of pharmacokinetics and metabolism of the drug. Severe side effects were encountered, which could be explained by the reduced clearance of CPT-11 and its metabolites. These included neutropenic fever with culture-proven septicemia, thrombocytopenia, somnolence, diarrhea, and signs and symptoms of transient hepatic failure. Our findings offer important data for the further development of guidelines for dose reduction of CPT-11 in patients with liver dysfunction.
- 17 July 1999
- Vol. 143 (29) , 1499-502
[National cancer fund (Koningin Wilhelmina Fonds) justifiably calls for continued focus on the cancer problem in Netherlands].
In the Netherlands, cancer will remain a significant issue in health care according to a signalling commission of the Dutch national cancer fund (Nederlandse Kankerbestrijding/Koningin Wilhelmina Fonds). If smoking would be abandoned, the incidence of lung cancer would drop dramatically. The role of food in carcinogenesis appears to be much less than was earlier believed. Chemoprevention will also have very limited influence on cancer incidence. Attempts at early diagnosis of cancer have been so far successful only in patients with breast cancer over 50 years of age and in cervical cancer. More effective therapies for cancer are urgently needed. The cost-effectiveness of adjuvant chemotherapy in breast cancer and colon cancer is unfavourable. Determination of better prognostic factors may reduce the number of patients who unnecessarily undergo this treatment. New anticancer drugs tend to be very expensive and this lays a heavy burden on health care budgets. Efficacy of new treatments needs to be compared with established ones in randomized trials before reimbursement can be granted.
- 17 July 1999
- Vol. 143 (29) , 1499-502
[National cancer fund (Koningin Wilhelmina Fonds) justifiably calls for continued focus on the cancer problem in Netherlands].
In the Netherlands, cancer will remain a significant issue in health care according to a signalling commission of the Dutch national cancer fund (Nederlandse Kankerbestrijding/Koningin Wilhelmina Fonds). If smoking would be abandoned, the incidence of lung cancer would drop dramatically. The role of food in carcinogenesis appears to be much less than was earlier believed. Chemoprevention will also have very limited influence on cancer incidence. Attempts at early diagnosis of cancer have been so far successful only in patients with breast cancer over 50 years of age and in cervical cancer. More effective therapies for cancer are urgently needed. The cost-effectiveness of adjuvant chemotherapy in breast cancer and colon cancer is unfavourable. Determination of better prognostic factors may reduce the number of patients who unnecessarily undergo this treatment. New anticancer drugs tend to be very expensive and this lays a heavy burden on health care budgets. Efficacy of new treatments needs to be compared with established ones in randomized trials before reimbursement can be granted.
- 30 September 1997
- Published by Elsevier in European Journal of Cancer
- Vol. 33, S244
1104: A phase I study with S-1, an oral 5-FU formulation, in patients with solid tumors
- 30 September 1997
- Published by Elsevier in European Journal of Cancer
- Vol. 33, S244
1104: A phase I study with S-1, an oral 5-FU formulation, in patients with solid tumors
- Open Access
- 1 September 1994
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 12 (9) , 1745-1747
Vinorelbine: a horse of a different color?
- 1 September 1994
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 12 (9) , 1745-1747
Open AccessVinorelbine: a horse of a different color?
- 1 April 1994
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 12 (4) , 812-819
Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil.
To achieve an adequate plasma concentration of bepridil, a calcium channel blocker, which reverts multidrug resistance (MDR) in vitro, when administered in combination with vinblastine in patients with advanced colorectal cancer, a tumor characterized by high MDR1 gene expression. To study the pharmacokinetics of both drugs, tolerability and antitumor activity in relation to the MDR1 expression in tumor tissue. Sixteen colorectal cancer patients entered the study. Bepridil was administered by central venous catheter as 5-mg/kg bolus over 30 minutes, followed by 12 mg/kg for 12 hours and 5 mg/kg for 24 hours. Vinblastine 5 mg/m2 was administered as an intravenous (i.v.) bolus 24.5 hours after the start of bepridil. MDR1/P-glycoprotein (Pgp) expression was assessed in 14 tumor samples by immunohistochemistry and RNase protection assay. The bepridil plasma level was greater than 2 mumol/L at the time of vinblastine administration in all patients investigated. At the dose used in the study, bepridil produced a QTc-prolongation more than 50 ms, which prevented further dose escalation. However, cardiac toxicity was asymptomatic in all treated patients, and other side effects were mild. MDR1/Pgp expression was positive in nine of 14 cases. Of fifteen patients assessable for response, one complete remission of 8 months' duration and 14 progressions were observed. The responding patient attained complete remission again when re-treated on progression with vinblastine alone. Bepridil plasma concentrations needed in vitro to modulate MDR could be achieved in this study with tolerable toxicity; however, despite most tumors being MDR1/Pgp-positive, no response was obtained that could be attributed to the drug combination. Mechanisms of drug resistance other than MDR are probably implicated in drug resistance of colorectal cancer.
- 1 April 1994
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 12 (4) , 812-819
Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil.
To achieve an adequate plasma concentration of bepridil, a calcium channel blocker, which reverts multidrug resistance (MDR) in vitro, when administered in combination with vinblastine in patients with advanced colorectal cancer, a tumor characterized by high MDR1 gene expression. To study the pharmacokinetics of both drugs, tolerability and antitumor activity in relation to the MDR1 expression in tumor tissue. Sixteen colorectal cancer patients entered the study. Bepridil was administered by central venous catheter as 5-mg/kg bolus over 30 minutes, followed by 12 mg/kg for 12 hours and 5 mg/kg for 24 hours. Vinblastine 5 mg/m2 was administered as an intravenous (i.v.) bolus 24.5 hours after the start of bepridil. MDR1/P-glycoprotein (Pgp) expression was assessed in 14 tumor samples by immunohistochemistry and RNase protection assay. The bepridil plasma level was greater than 2 mumol/L at the time of vinblastine administration in all patients investigated. At the dose used in the study, bepridil produced a QTc-prolongation more than 50 ms, which prevented further dose escalation. However, cardiac toxicity was asymptomatic in all treated patients, and other side effects were mild. MDR1/Pgp expression was positive in nine of 14 cases. Of fifteen patients assessable for response, one complete remission of 8 months' duration and 14 progressions were observed. The responding patient attained complete remission again when re-treated on progression with vinblastine alone. Bepridil plasma concentrations needed in vitro to modulate MDR could be achieved in this study with tolerable toxicity; however, despite most tumors being MDR1/Pgp-positive, no response was obtained that could be attributed to the drug combination. Mechanisms of drug resistance other than MDR are probably implicated in drug resistance of colorectal cancer.